KERLEDEX
LOE ApproachingNDAORALTABLET
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERLEDEX is an oral small-molecule tablet approved in 1992 by Sanofi under NDA status. The specific indication, mechanism of action, and pharmacologic class are not publicly disclosed in available data. Patient population and clinical utility cannot be determined without additional therapeutic area context.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams are likely focused on managed decline and lifecycle extension rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KERLEDEX is a mature, LOE-approaching product with minimal open career opportunities; roles available focus on commercial sustainability, payer relations, and lifecycle extension rather than growth and innovation. Career growth potential is limited; this assignment is best suited for experienced professionals managing market transitions or those seeking stability in a stable, declining franchise.
Brand Manager
Worked on KERLEDEX at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.